The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Antibody therapeutics are a large and rapidly expanding drug class providing major health
benefits. We provide a snapshot of current antibody therapeutics including their formats …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Members of the human epidermal growth factor receptor (HER) family, which includes HER1
(also known as EGFR), HER2, HER3 and HER4, have played a central role in regulating cell …

The intact antibody of human immunoglobulin (IgG) is composed of the fragment for antigen
binding (Fab) and the crystallizable fragment (Fc) for binding of Fcγ receptors. Among the …

In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents
to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a …

Therapeutic monoclonal antibodies and their derivatives are key components of clinical
pipelines in the global biopharmaceutical industry. The availability of large datasets of …

The emergence of antimicrobial resistance (AMR) is rapidly increasing and it is one of the
significant twenty-first century's healthcare challenges. Unfortunately, the development of …

Introduction We describe a new, third-generation of antibody-drug conjugates (ADCs)
having a high drug payload against topoisomerase I, important for DNA function, and …

Cancer is one of the deadliest diseases, causing million of deaths each year globally.
Conventional anti-cancer therapies are non-targeted and have systemic toxicities limiting …